Abstract: The present disclosure relates to injectable compositions and methods of making injectable compositions of moisture curing siloxane polymers for forming accommodating intraocular lenses. In certain embodiments, the moisture curing siloxane polymers are comprised of an organosilicon compound and a hydrolytically sensitive siloxane moiety and have a specific gravity of greater than about 0.95, a number average molecular weight (Mn) greater than about 5,000 or about 20,000 and a weight average molecular weight (Mw) greater than about 20,000 or about 40,000. The disclosure includes accommodating intraocular lenses formed from moisture curing siloxane polymers and having a modulus of elasticity of less than about 6 kPa, less than 20% post-cure extractables, refractive index ranging from 1.4 to 1.5 and dioptric range of accommodation of 0D to 10D.

Abstract: Described are embodiments that include methods and devices for detecting disposables that may be used in medical devices. Embodiments involve the detection of disposables used in apheresis machines. The disposable are configured to fit into portions, or features, of the apheresis machines in predetermined ways and embodiments provide for detecting whether the disposable have been loaded correctly.

Abstract: The present disclosure relates to injectable compositions and methods of making injectable compositions of moisture curing siloxane polymers for forming accommodating intraocular lenses. In certain embodiments, the moisture curing siloxane polymers are comprised of an organosilicon compound and a hydrolytically sensitive siloxane moiety and have a specific gravity of greater than about 0.95, a number average molecular weight (Mn) greater than about 5,000 or about 20,000 and a weight average molecular weight (Mw) greater than about 20,000 or about 40,000. The disclosure includes accommodating intraocular lenses formed from moisture curing siloxane polymers and having a modulus of elasticity of less than about 6 kPa, less than 20% post-cure extractables, refractive index ranging from 1.4 to 1.5 and dioptric range of accommodation of 0D to 10D.

Abstract: The present disclosure relates to injectable compositions and methods of making injectable compositions of moisture curing siloxane polymers for forming accommodating intraocular lenses. In certain embodiments, the moisture curing siloxane polymers are comprised of an organosilicon compound and a hydrolytically sensitive siloxane moiety and have a specific gravity of greater than about 0.95, a number average molecular weight (Mn) greater than about 5,000 or about 20,000 and a weight average molecular weight (Mw) greater than about 20,000 or about 40,000. The disclosure includes accommodating intraocular lenses formed from moisture curing siloxane polymers and having a modulus of elasticity of less than about 6 kPa, less than 20% post-cure extractables, refractive index ranging from 1.4 to 1.5 and dioptric range of accommodation of OD to 10D.

Abstract: The invention provides an additive for lowering the minimum usable temperature of a biodiesel fuel or a diesel/biodiesel blend. The additive comprises at least one saccharide ester and a polymer having a comb structure. In some instances there is only one saccharide ester present. In this case the saccharide ester comprises at least one saturated ester group and at least one unsaturated ester group. In other instances, there is more than one saccharide ester is present. In these cases the additive comprises a first saccharide ester comprising at least one saturated ester group and a second saccharide ester comprising at least one unsaturated ester group.

Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds. The invention also relates to methods of modulating the function of protein tyrosine kinases using indolinone compounds and methods of treating diseases by modulating the function of protein tyrosine kinases and related signal transduction pathways.

Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The present invention relates to novel 3-methylidenyl-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The present invention relates to novel geometrically restricted 2-indolinones and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

Abstract: The present invention relates to pharmaceutical formulations containing (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2 -one (-)-2',3'-dideoxy,3'-thiacytidine, lamivudine, that are substantially free of ethanol and ethylenediamine-tetraacitic acid, and their use in medical therapy.